Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Tenovins are known to inhibit sirtuin activity, potentially increasing p53 acetylation and stability.
• Previous studies indicate some tenovins also inhibit autophagic flux, suggesting multiple molecular targets.
• The tumor suppressor p53 plays a critical role in cancer, and understanding its regulation is key to developing new therapies.

Purpose of the Study:

• To identify additional mechanisms by which tenovins activate p53 and induce tumor cell death.
• To investigate the role of dihydroorotate dehydrogenase (DHODH) and uridine transport in tenovin's mechanism of action.
• To provide a more comprehensive understanding of tenovin's molecular targets and their implications in cancer research.

Main Methods:

• Cell culture experiments to assess tumor cell viability.
• Enzyme inhibition assays to evaluate tenovin's effect on DHODH.
• Uridine uptake assays to measure tenovin's impact on uridine transport.
• Western blotting to analyze p53 levels and acetylation.

Main Results:

• Tenovins were found to inhibit dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis.
• Tenovins were also shown to block uridine transport into cells.
• These actions contribute to the activation of p53 and subsequent tumor cell death.
• The study highlights that tenovins can activate p53 through multiple pathways beyond sirtuin inhibition.

Conclusions:

• Tenovins possess multiple mechanisms for activating p53, including DHODH inhibition and disruption of uridine transport.
• These findings necessitate a re-evaluation of previous studies on tenovins as sirtuin inhibitors, considering DHODH inhibition as a major contributing factor.
• Subtle structural modifications in small molecules can significantly alter their target profiles, even if the overall cellular effect appears consistent.